MX2011010976A - Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion. - Google Patents

Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion.

Info

Publication number
MX2011010976A
MX2011010976A MX2011010976A MX2011010976A MX2011010976A MX 2011010976 A MX2011010976 A MX 2011010976A MX 2011010976 A MX2011010976 A MX 2011010976A MX 2011010976 A MX2011010976 A MX 2011010976A MX 2011010976 A MX2011010976 A MX 2011010976A
Authority
MX
Mexico
Prior art keywords
vaccines
attenuation
mycoplasma bovis
attenuated
bovis
Prior art date
Application number
MX2011010976A
Other languages
English (en)
Other versions
MX342443B (es
Inventor
Jeffrey KNITTEL
Michael Beck
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of MX2011010976A publication Critical patent/MX2011010976A/es
Publication of MX342443B publication Critical patent/MX342443B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a nuevas cepas bacterianas de M. bovis atenuadas sometidas a pases al menos 110 veces. Además, la presente invención también proporciona composiciones inmunogénicas que comprenden bacterias vivas de cualquiera de estas cepas bacterianas de M. bovis atenuadas, su fabricación y uso para el tratamiento y profilaxis de infecciones por M. bovis y combinaciones con otras vacunas o medicamentos de uso veterinario.
MX2011010976A 2009-04-24 2010-04-23 Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion. MX342443B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17254309P 2009-04-24 2009-04-24
PCT/US2010/032149 WO2010124154A1 (en) 2009-04-24 2010-04-23 Vaccines comprising attenuated mycoplasma bovis strains and method for the attenuation

Publications (2)

Publication Number Publication Date
MX2011010976A true MX2011010976A (es) 2011-11-18
MX342443B MX342443B (es) 2016-09-29

Family

ID=42331013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010976A MX342443B (es) 2009-04-24 2010-04-23 Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion.

Country Status (20)

Country Link
US (1) US9339533B2 (es)
EP (1) EP2421556B1 (es)
JP (1) JP5793808B2 (es)
KR (1) KR101880888B1 (es)
CN (1) CN102458461B (es)
AR (1) AR076413A1 (es)
AU (1) AU2010238689B2 (es)
BR (1) BRPI1013836B1 (es)
CA (1) CA2758733C (es)
CL (1) CL2011002639A1 (es)
CO (1) CO6460761A2 (es)
DK (1) DK2421556T3 (es)
ES (1) ES2630209T3 (es)
HU (1) HUE033618T2 (es)
MX (1) MX342443B (es)
NZ (1) NZ595914A (es)
PL (1) PL2421556T3 (es)
SG (2) SG10201401784WA (es)
UY (1) UY32570A (es)
WO (1) WO2010124154A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030619A2 (en) * 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
EP2362780B1 (en) 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
CA2699024C (en) * 2009-11-06 2016-12-13 Intervet International B.V. Methods of immunizing pregnant heifers at three months of gestation
CN102294026A (zh) * 2010-11-17 2011-12-28 赤峰博恩药业有限公司 奶牛链球菌乳房炎灭活疫苗及其制备方法
US9175049B2 (en) 2012-10-24 2015-11-03 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
EP3085771B1 (en) 2013-12-18 2020-01-22 Asahi Kasei Kabushiki Kaisha Method for detecting bacteria of the genus streptococcus in milk
CN103800901B (zh) * 2014-01-27 2015-12-09 内蒙古华希生物科技有限公司 链球菌以及将其灭活得到的奶牛乳房炎疫苗
WO2017030901A1 (en) 2015-08-14 2017-02-23 Zoetis Services Llc Mycoplasma bovis compositions
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
CN107815439A (zh) * 2016-09-14 2018-03-20 华威特（江苏）生物制药有限公司 牛传染性鼻气管炎病毒jsm株及其应用
CN107759674B (zh) * 2017-09-26 2021-12-28 中国农业科学院哈尔滨兽医研究所 一种牛支原体免疫相关性蛋白、含有该蛋白的检测试剂盒及其在牛支原体抗体检测中的用途
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN109847060A (zh) * 2019-04-19 2019-06-07 黑龙江八一农垦大学 牛多杀性巴氏杆菌病、溶血性曼氏杆菌病二联灭活疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111733094B (zh) * 2020-05-29 2022-09-09 内蒙古民族大学 一种牛源蜡样芽孢杆菌及其应用
AR124849A1 (es) 2021-02-11 2023-05-10 Intervet Int Bv Vacuna para mycoplasma bovis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994944A1 (en) 1997-07-10 2000-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
EP1229929A2 (en) * 1999-11-08 2002-08-14 Biomune VACCINES FOR i MYCOPLASMA BOVIS /i AND METHODS OF USE
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
US20030147914A1 (en) * 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
JP2004537543A (ja) * 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
JP2005500845A (ja) 2001-08-28 2005-01-13 ファイザー・プロダクツ・インク マイコプラズマ・ボビスチャレンジモデル並びにマイコプラズマ・ボビスの投与方法及び肺炎性肺病変の誘発方法
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) * 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
WO2008030619A2 (en) 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
CN100419073C (zh) * 2006-09-28 2008-09-17 中国兽医药品监察所 猪喘气病活疫苗及其生产方法
CL2008002675A1 (es) * 2007-09-11 2008-11-07 Wyeth Corp Bacteria de mycoplasma gallisepticum atenuada; composicion de vacuna que la comprende; método de vacunación; y método de identificación de clones de mycoplasma gallisepticum atenuados.
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
EP2320943B1 (en) 2008-07-03 2016-02-17 Iowa State University Research Foundation, Inc. Cattle vaccines
EP2362780B1 (en) * 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
BRPI1013836B1 (pt) 2020-04-14
CA2758733A1 (en) 2010-10-28
WO2010124154A1 (en) 2010-10-28
JP2012524548A (ja) 2012-10-18
CN102458461A (zh) 2012-05-16
ES2630209T3 (es) 2017-08-18
US9339533B2 (en) 2016-05-17
US20100272759A1 (en) 2010-10-28
KR20120109992A (ko) 2012-10-09
AU2010238689A1 (en) 2011-11-03
MX342443B (es) 2016-09-29
CL2011002639A1 (es) 2012-07-20
UY32570A (es) 2010-11-30
SG10201401784WA (en) 2014-08-28
EP2421556A1 (en) 2012-02-29
AR076413A1 (es) 2011-06-08
AU2010238689B2 (en) 2017-01-19
JP5793808B2 (ja) 2015-10-14
CN102458461B (zh) 2017-03-08
CO6460761A2 (es) 2012-06-15
CA2758733C (en) 2019-12-24
HUE033618T2 (en) 2017-12-28
NZ595914A (en) 2014-09-26
DK2421556T3 (en) 2017-07-10
PL2421556T3 (pl) 2017-09-29
EP2421556B1 (en) 2017-04-05
KR101880888B1 (ko) 2018-07-23
SG175323A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
MX2011010976A (es) Vacunas que comprenden cepas de mycoplasma bovis atenuadas y metodo para la atenuacion.
MX2010003719A (es) Vacuna de mycoplasma bovis y metodos de uso de la misma.
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
PH12018501221A1 (en) Mixture of hmos
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
CL2011002852A1 (es) Uso de bacterias del acido lactico probioticas por un tratamiento con calor para la preparacion de composiciones para prevenir o tratar inmunodeficiencias causadas por infecciones bacterianas, virales, fungicas y/o parasitarias.
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX354047B (es) Cepas/celulas de lactobacillus secadas por aspersion, y el uso de las mismas contra helicobacter pylori.
PH12016501879B1 (en) Immunological composition containing attenuated histophilus somni
MY173796A (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
UA98506C2 (en) Attenuated mycoplasma gallisepticum strains
EP4100058A4 (en) IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF MICROBIAL INFECTIONS
MX2017016401A (es) Composiciones inmunogenas.
EP2538970A4 (en) TREATMENT OR PREVENTION OF INFECTION
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
MX2022003871A (es) Composiciones inmunogénicas.
MX2015005112A (es) Composicion inmunogenica contra la aeromonas hydrophila.
CA3156472A1 (en) POLYMER COMPOSITION
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
BR112015011944A8 (pt) linhagem bacteriana atenuada estável, seus usos e método para sua geração, composição de vacina
TH135890A (th) วัคซีนเชื้อเป็นที่ได้รับการดัดแปรปรับปรุงของ Mycoplasma bovis, วิธีการผลิตวัคซีน เชื้อเป็นที่ได้รับการดัดแปรของ Mycoplasma bovis, วัคซีนรวม และวิธีการรักษา
WO2014033625A3 (en) Oral care

Legal Events

Date Code Title Description
FG Grant or registration